View in EDS HTML Full Text PDF Full Text

HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial.

Saved in:
Bibliographic Details
Title: HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial.
Authors: Altena R; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Wiklander OPB; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; Breast Center, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden., Romdhani NS; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Kistner A; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Klintman M; Division of Oncology, Department of Clinical Sciences, Lund University, and Skåne University Hospital, Lund, Sweden., Skarping I; Division of Oncology, Department of Clinical Sciences, Lund University, and Skåne University Hospital, Lund, Sweden.; Department of Clinical Physiology and Nuclear Medicine, Skane University Hospital, Lund, Sweden., Lindman H; Department of Oncology, Uppsala University hospital, Uppsala, Sweden., Rodriguez VS; Division of Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden., Frisell O; The Swedish Institute for Health Economics, Stockholm, Sweden.; Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Solna, Sweden., Lindgren P; The Swedish Institute for Health Economics, Stockholm, Sweden.; Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Solna, Sweden., Bratteby K; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Jussing E; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Feldwisch J; Affibody AB, Stockholm, Sweden., Frejd FY; Affibody AB, Stockholm, Sweden.; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Cascales HS; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Siikanen J; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Hindorf C; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Tran TA; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden.
Source: Frontiers in oncology [Front Oncol] 2026 Apr 10; Vol. 16, pp. 1812711. Date of Electronic Publication: 2026 Apr 10 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42038396
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Altena+R%22">Altena R</searchLink>; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Wiklander+OPB%22">Wiklander OPB</searchLink>; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; Breast Center, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Romdhani+NS%22">Romdhani NS</searchLink>; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Kistner+A%22">Kistner A</searchLink>; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Klintman+M%22">Klintman M</searchLink>; Division of Oncology, Department of Clinical Sciences, Lund University, and Skåne University Hospital, Lund, Sweden.<br /><searchLink fieldCode="AU" term="%22Skarping+I%22">Skarping I</searchLink>; Division of Oncology, Department of Clinical Sciences, Lund University, and Skåne University Hospital, Lund, Sweden.; Department of Clinical Physiology and Nuclear Medicine, Skane University Hospital, Lund, Sweden.<br /><searchLink fieldCode="AU" term="%22Lindman+H%22">Lindman H</searchLink>; Department of Oncology, Uppsala University hospital, Uppsala, Sweden.<br /><searchLink fieldCode="AU" term="%22Rodriguez+VS%22">Rodriguez VS</searchLink>; Division of Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.<br /><searchLink fieldCode="AU" term="%22Frisell+O%22">Frisell O</searchLink>; The Swedish Institute for Health Economics, Stockholm, Sweden.; Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Solna, Sweden.<br /><searchLink fieldCode="AU" term="%22Lindgren+P%22">Lindgren P</searchLink>; The Swedish Institute for Health Economics, Stockholm, Sweden.; Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Solna, Sweden.<br /><searchLink fieldCode="AU" term="%22Bratteby+K%22">Bratteby K</searchLink>; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Jussing+E%22">Jussing E</searchLink>; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Feldwisch+J%22">Feldwisch J</searchLink>; Affibody AB, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Frejd+FY%22">Frejd FY</searchLink>; Affibody AB, Stockholm, Sweden.; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.<br /><searchLink fieldCode="AU" term="%22Cascales+HS%22">Cascales HS</searchLink>; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Siikanen+J%22">Siikanen J</searchLink>; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Hindorf+C%22">Hindorf C</searchLink>; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Tran+TA%22">Tran TA</searchLink>; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2026 Apr 10; Vol. 16, pp. 1812711. <i>Date of Electronic Publication: </i>2026 Apr 10 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42038396
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2026.1812711
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1812711
    Titles:
      – TitleFull: HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Altena R
      – PersonEntity:
          Name:
            NameFull: Wiklander OPB
      – PersonEntity:
          Name:
            NameFull: Romdhani NS
      – PersonEntity:
          Name:
            NameFull: Kistner A
      – PersonEntity:
          Name:
            NameFull: Klintman M
      – PersonEntity:
          Name:
            NameFull: Skarping I
      – PersonEntity:
          Name:
            NameFull: Lindman H
      – PersonEntity:
          Name:
            NameFull: Rodriguez VS
      – PersonEntity:
          Name:
            NameFull: Frisell O
      – PersonEntity:
          Name:
            NameFull: Lindgren P
      – PersonEntity:
          Name:
            NameFull: Bratteby K
      – PersonEntity:
          Name:
            NameFull: Jussing E
      – PersonEntity:
          Name:
            NameFull: Feldwisch J
      – PersonEntity:
          Name:
            NameFull: Frejd FY
      – PersonEntity:
          Name:
            NameFull: Cascales HS
      – PersonEntity:
          Name:
            NameFull: Siikanen J
      – PersonEntity:
          Name:
            NameFull: Hindorf C
      – PersonEntity:
          Name:
            NameFull: Tran TA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 04
              Text: 2026 Apr 10
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1